Bengaluru-based Avesthagen Limited has launched AVGEN Diagnostics, the first fully integrated end-to-end personalized genetic testing service. The innovative platform employs the latest in next-generation sequencing (NGS) technology and artificial intelligence (AI) driven precision analytics that drive diagnostic testing services at B2C, B2B levels forging partnerships with hospitals, private clinics and health insurers.

AVGEN Diagnostics address the $15 billion global genetic diagnostic testing market through AvestaScan, its portfolio of NGS-driven tests that cover Whole Genome Sequencing, Whole Exome Sequencing and CALiBRx (Directed Panel Sequencing) for early diagnosis and risk management of heritable conditions.

The portfolio addresses Cancers, Cardiac Care Diagnostics, Neurodegenerative conditions, Autoimmune conditions, Rare diseases, pharmacogenomics, ancestry analysis and a unique set of tests for women’s health – reproductive genomics and fertility testing, Carrier Screening, and Pre-Natal Diagnostics with precision analytics powered by Congenica, UK a digital health company, that enables precision medicine through its AI-powered diagnostic decision support platform for genomic data.

AVGEN Diagnostics will be uniquely supported by the R&D outcomes of its flagship, The Avestagenome Project, which will provide accelerated and continuous innovation to create a pipeline of novel diagnostic tests, enabling best-in-class patient care.  The Avestagenome Project uses Congenica’s variant prioritization platform for its projects that include screening of the Zoroastrian Parsi Female Reference Genome and the Male Reference Genome for Clinically actionable variants, Clinical study of Pancreatitis, Type 1 Diabetes and Ulcerative Colitis among Zoroastrian Parsi family cohorts from The Avestagenome Project.

Original Source: BioSpectrum